Snapshot evaluation of acute and chronic heart failure in real-life in Turkey: A follow-up data for mortality

Objective: Heart failure (HF) is a progressive clinical syndrome. SELFIE-TR is a registry illustrating the overall HF patient profile of Turkey. Herein,all-cause mortality (ACM) data during follow-up were provided.Methods: This is a prospective outcome analysis of SELFIE-TR. Patients were classified as acute HF (AHF) versus chronic HF (CHF) and HF withreduced ejection fraction (HFrEF), HF with mid-range ejection fraction, and HF with preserved ejection fraction and were followed up for ACM.Results: There were 1054 patients with a mean age of 63.3±13.3 years and with a median follow-up period of 16 (7–17) months. Survival datawithin 1 year were available in 1022 patients. Crude ACM was 19.9% for 1 year in the whole group. ACM within 1 year was 13.7% versus 32.6%in patients with CHF and AHF, respectively (p<0.001). Angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, beta blocker, andmineralocorticoid receptor antagonist were present in 70.6%, 88.2%, and 50.7%, respectively. In the whole cohort, survival curves were gradedaccording to guideline-directed medical therapy (GDMT) scores ≤1 versus 2 versus 3 as 28% versus 20.2% versus 12.2%, respectively (p<0.001).Multivariate analysis of the whole cohort yielded age (p=0.009) and AHF (p=0.028) as independent predictors of mortality in 1 year.Conclusion: One-year mortality is high in Turkish patients with HF compared with contemporary cohorts with AHF and CHF. Of note, GDMT scoreis influential on 1-year mortality being the most striking one on chronic HFrEF. On the other hand, in the whole cohort, age and AHF were the onlyindependent predictors of death in 1 year

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Değertekin M, Erol C, Ergene O, Tokgözoğlu L, Aksoy M, Erol MK, et al. Heart failure prevalence and predictors in Turkey: HAPPY study. Turk Kardiyol Dern Ars 2012; 40: 298-308.
2. Tokgözoğlu L, Kayıkçıoğlu M, Altay S, Aydoğdu S, Barçın C, Bostan C, et al. [EUROASPIRE-IV: European Society of Cardiology study of lifestyle, risk factors, and treatment approaches in patients with coronary artery disease: Data from Turkey]. Turk Kardiyol Dern Ars 2017; 45: 134-44.
3. Yılmaz MB, Çelik A, Çavuşoğlu Y, Bekar L, Onrat E, Eren M, et al. Snapshot evaluation of heart failure in Turkey: Baseline characteristics of SELFIE-TR. Turk Kardiyol Dern Ars 2019; 47: 198-206.
4. Zoghi M, Kaya H, Çavuşoğlu Y, Aksakal E, Demir Ş, Yücel C, et al. Frequency of genetic polymorphism for adrenergic receptor beta and cytochrome p450 2D6 enzyme, and effects on tolerability of beta-blocker therapy in heart failure with reduced ejection fraction patients: The Beta GenTURK study. Turk Kardiyol Dern Ars 2016; 44: 457-65.
5. Komajda M, Böhm M, Borer JS, Ford I, Tavazzi L, Pannaux M, et al. Incremental benefit of drug therapies for chronic heart failure with reduced ejection fraction: a network meta-analysis. Eur J Heart Fail 2018; 20: 1315-22.
6. Balakumaran K, Patil A, Marsh S, Ingrassia J, Kuo CL, Jacoby DL, et al. Evaluation of a guideline directed medical therapy titration program in patients with heart failure with reduced ejection fraction. Int J Cardiol Heart Vasc 2018; 22: 1-5.
7. Fiuzat M, Sbolli M, Cani DS, O'Connor C, Abraham W, Psotka M, et al. Guideline Directed Medical Therapy in Heart Failure Trials: A New Proposed Scoring System. Journal of Cardiac Failure 2019; 25: S77.
8. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart 2007; 93: 1137-46.
9. Bleumink GS, Knetsch AM, Sturkenboom MC, Straus SM, Hofman A, Deckers JW, et al. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study. Eur Heart J 2004; 25: 1614-9.
10. Ceia F, Fonseca C, Mota T, Morais H, Matias F, de Sousa A, et al.; EPICA Investigators. Prevalence of chronic heart failure in Southwestern Europe: the EPICA study. Eur J Heart Fail 2002; 4: 531-9.
11. Cowie MR, Mosterd A, Wood DA, Deckers JW, Poole-Wilson PA, Sutton GC, et al. The epidemiology of heart failure. Eur Heart J 1997; 18: 208-25.
12. Mosterd A, Reitsma JB, Grobbee DE. Angiotensin converting enzyme inhibition and hospitalisation rates for heart failure in the Netherlands, 1980 to 1999: the end of an epidemic? Heart 2002; 87: 75-6.
13. Maggioni AP, Dahlström U, Filippatos G, Chioncel O, Leiro MC, Drozdz J, et al.; Heart Failure Association of ESC (HFA). EURObservational Research Programme: the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail 2010; 12: 1076-84.
14. Tavazzi L, Senni M, Metra M, Gorini M, Cacciatore G, Chinaglia A, et al. Multicenter prospective observational study on acute and chronic heart failure: one-year follow-up results of IN-HF (Italian Network on Heart Failure) outcome registry. Circ Heart Fail 2013; 6: 473-81.
15. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al.; ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37: 2129-200.
16. SOLVD Investigators, Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302.
17. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429-35.
18. [No authors listed]. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 1993; 342: 821-8.
19. Køber L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995; 333: 1670-6.
20. Packer M, Poole-Wilson PA, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999; 100: 2312-8.
21. Velazquez EJ, Pfeffer MA, McMurray JV, Maggioni AP, Rouleau JL, Van de Werf F, et al.; VALIANT Investigators. VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context. Eur J Heart Fail 2003; 5: 537-44.
22. Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667-75.
23. McMurray J, Ostergren J, Pfeffer M, Swedberg K, Granger C, Yusuf S, et al.; CHARM committees and investigators. Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur J Heart Fail 2003; 5: 261-70.
24. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582-7.
25. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334: 1349-55.
26. Eichhorn EJ, Bristow MR. The Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Curr Control Trials Cardiovasc Med 2001; 2: 20-3.
27. [No authors listed]. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-7.
28. [No authors listed]. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353: 9-13.
29. Beta-Blocker Evaluation of Survival Trial Investigators, Eichhorn EJ, Domanski MJ, Krause-Steinrauf H, Bristow MR, Lavori PW. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001; 344: 1659-67.
30. Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, et al.; SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005; 26: 215-25.
31. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-17.
32. Pitt B, Williams G, Remme W, Martinez F, Lopez-Sendon J, Zannad F, et al. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther 2001; 15: 79-87.
33. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al.; EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364: 11-21.
34. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, et al.; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 62: e147-239.
35. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Colvin MM, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 2017; 136: e137-61.
36. Burnett H, Earley A, Voors AA, Senni M, McMurray JJ, Deschaseaux C, et al. Thirty Years of Evidence on the Efficacy of Drug Treatments for Chronic Heart Failure With Reduced Ejection Fraction: A Network Meta-Analysis. Circ Heart Fail 2017; 10: pii: e003529.
37. Pocock SJ, Ariti CA, McMurray JJ, Maggioni A, Køber L, Squire IB, et al.; Meta-Analysis Global Group in Chronic Heart Failure. Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. Eur Heart J 2013; 34: 1404-13.
38. Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. Eur Heart J 2012; 33: 1750-7.
39. Barlera S, Tavazzi L, Franzosi MG, Marchioli R, Raimondi E, Masson S, et al. Predictors of mortality in 6975 patients with chronic heart failure in the Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico-Heart Failure trial: proposal for a nomogram. Circ Heart Fail 2013; 6: 31-9.
40. Fonarow GC; ADHERE Scientific Advisory Committee. The Acute Decompensated Heart Failure National Registry (ADHERE): opportunities to improve care of patients hospitalized with acute decompensated heart failure. Rev Cardiovasc Med 2003; 4 Suppl 7: S21-30.
41. Nieminen MS, Brutsaert D, Dickstein K, Drexler H, Follath F, Harjola VP, et al.; EuroHeart Survey Investigators; Heart Failure Associa- tion, European Society of Cardiology. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J 2006; 27: 2725-36.
42. Cleland JGF, Swedberg K, Cohen-Solal A, Cosin-Aguilar J, Dietz R, Follath F, et al. The Euro Heart Failure Survey of the EUROHEART survey programme. A survey on the quality of care among patients with heart failure in Europe. The Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. The Medicines Evaluation Group Centre for Health Economics University of York. Eur J Heart Fail 2000; 2: 123-32.
43. Tran RH, Aldemerdash A, Chang P, Sueta CA, Kaufman B, AsafuAdjei J, et al. Guideline-Directed Medical Therapy and Survival Following Hospitalization in Patients with Heart Failure. Pharmacotherapy 2018; 38: 406-16.
44. Yamaguchi T, Kitai T, Miyamoto T, Kagiyama N, Okumura T, Kida K, et al. Effect of Optimizing Guideline-Directed Medical Therapy Before Discharge on Mortality and Heart Failure Readmission in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction. Am J Cardiol 2018; 121: 969-74.
45. Andronic AA, Mihaila S, Cinteza M. Heart Failure with Mid-Range Ejection Fraction - a New Category of Heart Failure or Still a Gray Zone. Maedica (Buchar) 2016; 11: 320-4.
46. Lopatin Y. Heart Failure with Mid-Range Ejection Fraction and How to Treat It. Card Fail Rev 2018; 4: 9-13.
47. Nadar SK, Tariq O. What is Heart Failure with Mid-range Ejection Fraction? A New Subgroup of Patients with Heart Failure. Card Fail Rev 2018; 4: 6-8.
48. Choi KH, Choi JO, Jeon ES, Lee GY, Choi DJ, Lee HY, et al. Guideline-Directed Medical Therapy for Patients With Heart Failure With Midrange Ejection Fraction: A Patient-Pooled Analysis From the Kor HF and Kor AHF Registries. J Am Heart Assoc 2018; 7: e009806.
49. Ilieșiu AM, Hodorogea AS. Treatment of Heart Failure with Preserved Ejection Fraction. Adv Exp Med Biol 2018; 1067: 67-87.
50. Yamamoto K. Pharmacological Treatment of Heart Failure with Preserved Ejection Fraction. Yonago Acta Med 2017; 60: 71-6.
51. Komajda M, Böhm M, Borer JS, Ford I, Tavazzi L, Pannaux M, et al. Incremental benefit of drug therapies for chronic heart failure with reduced ejection fraction: a network meta-analysis. Eur J Heart Fail 2018; 20: 1315-22.
52. Heart Failure Society of America, Lindenfeld J, Albert NM, Boehmer JP, Collins SP, Ezekowitz JA, et al. HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail 2010; 16: e1-194.
53. Givertz MM, Teerlink JR, Albert NM, Westlake Canary CA, Collins SP, Colvin-Adams M, et al. Acute Decompensated Heart Failure: Update on New and Emerging Evidence and Directions for Future Research. J Card Fail 2013; 19: 371-89.
54. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, et al.; Carvedilol Or Metoprolol European Trial Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003; 362: 7-13.
55. Butler J, Young JB, Abraham WT, Bourge RC, Adams KF Jr, Clare R, et al.; ESCAPE Investigators. Beta-Blocker Use and Outcomes Among Hospitalized Heart Failure Patients. J Am Coll Cardiol 2006; 47: 2462-9.
56. Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, et al.; OPTIMIZE-HF Investigators and Coordinators. Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: findings from the OPTIMIZE-HF program. J Am Coll Cardiol 2008; 52: 190-9.
57. Orso F, Baldasseroni S, Fabbri G, Gonzini L, Lucci D, D'Ambrosi C, et al.; Italian Survey on Acute Heart Failure Investigators. Role of beta-blockers in patients admitted for worsening heart failure in a real world setting: data from the Italian Survey on Acute Heart Failure. Eur J Heart Fail 2009; 11: 77-84.
58. Jondeau G, Neuder Y, Eicher JC, Jourdain P, Fauveau E, Galinier M, et al.; B-CONVINCED Investigators. B-CONVINCED: Beta-blocker CONtinuation Vs. INterruption in patients with Congestive heart failure hospitalizED for a decompensation episode. Eur Heart J 2009; 30: 2186-92.
59. Chioncel O, Lainscak M, Seferovic PM, Anker SD, Crespo-Leiro MG, Harjola VP, et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 2017; 19: 1574-85.
60. Lund LH, Claggett B, Liu J, Lam CS, Jhund PS, Rosano GM, et al. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. Eur J Heart Fail 2018; 20: 1230-9.
61. Khatib R, McKee M, Shannon H, Chow C, Rangarajan S, Teo K, et al. Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and lowincome countries: an analysis of the PURE study data. Lancet 2016; 387: 61-9.
62. Dokainish H, Teo K, Zhu J, Roy A, AlHabib KF, ElSayed A, et al. Global mortality variations in patients with heart failure: results from the International Congestive Heart Failure (INTER-CHF) prospective cohort study. Lancet Glob Health 2017; 5: e665-72.
63. Coles AH, Fisher K, Darling C, Yarzebski J, McManus DD, Gore JM, et al. Long-term survival for patients with acute decompensated heart failure according to ejection fraction findings. Am J Cardiol 2014; 114: 862-8.

APA	YILMAZ M, AKSAKAL E, aksu u, Altay H, YILDIRIM N, ÇELİK A, AKIL M, BEKAR L, VURAL M, ÇETİN GÜVENÇ R, OZER S, URAL D, Çavuşoğlu Y, Tokgozoglu L (2020). Snapshot evaluation of acute and chronic heart failure in real-life in Turkey: A follow-up data for mortality. , 160 - 168. 10.14744/AnatolJCardiol.2019.87894
Chicago	YILMAZ MEHMET BIRHAN,AKSAKAL Emrah,aksu ugur,Altay Hakan,YILDIRIM Nesligül,ÇELİK Ahmet,AKIL Mehmet Ata,BEKAR Lütfü,VURAL Mustafa Gökhan,ÇETİN GÜVENÇ Rengin,OZER SAVAS,URAL Dilek,Çavuşoğlu Yüksel,Tokgozoglu Lale Snapshot evaluation of acute and chronic heart failure in real-life in Turkey: A follow-up data for mortality. (2020): 160 - 168. 10.14744/AnatolJCardiol.2019.87894
MLA	YILMAZ MEHMET BIRHAN,AKSAKAL Emrah,aksu ugur,Altay Hakan,YILDIRIM Nesligül,ÇELİK Ahmet,AKIL Mehmet Ata,BEKAR Lütfü,VURAL Mustafa Gökhan,ÇETİN GÜVENÇ Rengin,OZER SAVAS,URAL Dilek,Çavuşoğlu Yüksel,Tokgozoglu Lale Snapshot evaluation of acute and chronic heart failure in real-life in Turkey: A follow-up data for mortality. , 2020, ss.160 - 168. 10.14744/AnatolJCardiol.2019.87894
AMA	YILMAZ M,AKSAKAL E,aksu u,Altay H,YILDIRIM N,ÇELİK A,AKIL M,BEKAR L,VURAL M,ÇETİN GÜVENÇ R,OZER S,URAL D,Çavuşoğlu Y,Tokgozoglu L Snapshot evaluation of acute and chronic heart failure in real-life in Turkey: A follow-up data for mortality. . 2020; 160 - 168. 10.14744/AnatolJCardiol.2019.87894
Vancouver	YILMAZ M,AKSAKAL E,aksu u,Altay H,YILDIRIM N,ÇELİK A,AKIL M,BEKAR L,VURAL M,ÇETİN GÜVENÇ R,OZER S,URAL D,Çavuşoğlu Y,Tokgozoglu L Snapshot evaluation of acute and chronic heart failure in real-life in Turkey: A follow-up data for mortality. . 2020; 160 - 168. 10.14744/AnatolJCardiol.2019.87894
IEEE	YILMAZ M,AKSAKAL E,aksu u,Altay H,YILDIRIM N,ÇELİK A,AKIL M,BEKAR L,VURAL M,ÇETİN GÜVENÇ R,OZER S,URAL D,Çavuşoğlu Y,Tokgozoglu L "Snapshot evaluation of acute and chronic heart failure in real-life in Turkey: A follow-up data for mortality." , ss.160 - 168, 2020. 10.14744/AnatolJCardiol.2019.87894
ISNAD	YILMAZ, MEHMET BIRHAN vd. "Snapshot evaluation of acute and chronic heart failure in real-life in Turkey: A follow-up data for mortality". (2020), 160-168. https://doi.org/10.14744/AnatolJCardiol.2019.87894

APA	YILMAZ M, AKSAKAL E, aksu u, Altay H, YILDIRIM N, ÇELİK A, AKIL M, BEKAR L, VURAL M, ÇETİN GÜVENÇ R, OZER S, URAL D, Çavuşoğlu Y, Tokgozoglu L (2020). Snapshot evaluation of acute and chronic heart failure in real-life in Turkey: A follow-up data for mortality. The Anatolian Journal of Cardiology, 23(3), 160 - 168. 10.14744/AnatolJCardiol.2019.87894
Chicago	YILMAZ MEHMET BIRHAN,AKSAKAL Emrah,aksu ugur,Altay Hakan,YILDIRIM Nesligül,ÇELİK Ahmet,AKIL Mehmet Ata,BEKAR Lütfü,VURAL Mustafa Gökhan,ÇETİN GÜVENÇ Rengin,OZER SAVAS,URAL Dilek,Çavuşoğlu Yüksel,Tokgozoglu Lale Snapshot evaluation of acute and chronic heart failure in real-life in Turkey: A follow-up data for mortality. The Anatolian Journal of Cardiology 23, no.3 (2020): 160 - 168. 10.14744/AnatolJCardiol.2019.87894
MLA	YILMAZ MEHMET BIRHAN,AKSAKAL Emrah,aksu ugur,Altay Hakan,YILDIRIM Nesligül,ÇELİK Ahmet,AKIL Mehmet Ata,BEKAR Lütfü,VURAL Mustafa Gökhan,ÇETİN GÜVENÇ Rengin,OZER SAVAS,URAL Dilek,Çavuşoğlu Yüksel,Tokgozoglu Lale Snapshot evaluation of acute and chronic heart failure in real-life in Turkey: A follow-up data for mortality. The Anatolian Journal of Cardiology, vol.23, no.3, 2020, ss.160 - 168. 10.14744/AnatolJCardiol.2019.87894
AMA	YILMAZ M,AKSAKAL E,aksu u,Altay H,YILDIRIM N,ÇELİK A,AKIL M,BEKAR L,VURAL M,ÇETİN GÜVENÇ R,OZER S,URAL D,Çavuşoğlu Y,Tokgozoglu L Snapshot evaluation of acute and chronic heart failure in real-life in Turkey: A follow-up data for mortality. The Anatolian Journal of Cardiology. 2020; 23(3): 160 - 168. 10.14744/AnatolJCardiol.2019.87894
Vancouver	YILMAZ M,AKSAKAL E,aksu u,Altay H,YILDIRIM N,ÇELİK A,AKIL M,BEKAR L,VURAL M,ÇETİN GÜVENÇ R,OZER S,URAL D,Çavuşoğlu Y,Tokgozoglu L Snapshot evaluation of acute and chronic heart failure in real-life in Turkey: A follow-up data for mortality. The Anatolian Journal of Cardiology. 2020; 23(3): 160 - 168. 10.14744/AnatolJCardiol.2019.87894
IEEE	YILMAZ M,AKSAKAL E,aksu u,Altay H,YILDIRIM N,ÇELİK A,AKIL M,BEKAR L,VURAL M,ÇETİN GÜVENÇ R,OZER S,URAL D,Çavuşoğlu Y,Tokgozoglu L "Snapshot evaluation of acute and chronic heart failure in real-life in Turkey: A follow-up data for mortality." The Anatolian Journal of Cardiology, 23, ss.160 - 168, 2020. 10.14744/AnatolJCardiol.2019.87894
ISNAD	YILMAZ, MEHMET BIRHAN vd. "Snapshot evaluation of acute and chronic heart failure in real-life in Turkey: A follow-up data for mortality". The Anatolian Journal of Cardiology 23/3 (2020), 160-168. https://doi.org/10.14744/AnatolJCardiol.2019.87894